EMA Authorised: Circadin (melatonin) — RAD Neurim Pharmaceuticals EEC SARL

View source ↗

Summary

The EMA authorised Circadin (melatonin) by RAD Neurim Pharmaceuticals EEC SARL for Sleep Initiation and Maintenance Disorders, with decision dated 07/07/2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Circadin (melatonin)

Snippet

Status: Authorised. Therapeutic area: Sleep Initiation and Maintenance Disorders. MAH: RAD Neurim Pharmaceuticals EEC SARL. Decision date: 07/07/2025